6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl]-3-pyridin-3-yl-pyrazolo[1,5-a]pyrimidine

ID: ALA117166

Chembl Id: CHEMBL117166

PubChem CID: 5329452

Max Phase: Preclinical

Molecular Formula: C24H25N5O

Molecular Weight: 399.50

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  c1cncc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)c1

Standard InChI:  InChI=1S/C24H25N5O/c1-2-11-28(12-3-1)13-14-30-22-8-6-19(7-9-22)21-16-26-24-23(17-27-29(24)18-21)20-5-4-10-25-15-20/h4-10,15-18H,1-3,11-14H2

Standard InChI Key:  CXMKJARIDJFGGI-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA117166

   Pyrazolo[1,5-a]pyrimidine 4g

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 399.50

Molecular Weight (Monoisotopic): 399.2059

AlogP: 4.32

#Rotatable Bonds: 6

Polar Surface Area: 55.55

Molecular Species: BASE

HBA: 6

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 8.81

CX LogP: 3.44

CX LogD: 2.02

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.48

Np Likeness Score: -1.54

References

1. Fraley ME, Rubino RS, Hoffman WF, Hambaugh SR, Arrington KL, Hungate RW, Bilodeau MT, Tebben AJ, Rutledge RZ, Kendall RL, McFall RC, Huckle WR, Coll KE, Thomas KA..  (2002)  Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics.,  12  (24): [PMID:12443771] [10.1016/s0960-894x(02)00827-2]

2. Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, Deng DY, Sachidanandan C, Bloch KD, Peterson RT..  (2008)  Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors.,  18  (15): [PMID:18621530] [10.1016/j.bmcl.2008.06.052]

Source

Source(1):

• Scientific Literature